Compare Neurocrine Biosciences Inc (NBIX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs RLX Technology Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while RLX Technology Inc trades at $1.77 (market cap $2.19B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.59% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RLX | |
|---|---|---|
Market Cap | $15.77B | $2.19B |
Sector | Health | Technology |
52-Week High | $185.50 | $2.69 |
52-Week Low | $123.10 | $1.76 |
Enterprise Value | $15.78B | $919.18M |
Dividend Yield | — | 5.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
RLX trades at $1.79, down 0.56% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue growth of 14.8% year-over-year, driven by international expansion, though it missed EPS estimates for the third consecutive quarter. Profitability remains solid with a net income margin of 21.87% and a P/E ratio of 16.1, indicating reasonable valuation.
The outlook is mixed; international growth offers opportunity, but consistent earnings misses and a sole 'Hold' analyst rating suggest caution. Key risks include execution in new markets and regulatory scrutiny. The stock lacks bullish momentum but holds fundamental strength if expansion delivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
